drugset / Trial / NCT01130532

A Study in Erectile Dysfunction

NCT01130532

Phase 4 Completed 623 enrolled Eli Lilly and Company
RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this trial is to evaluate if treatment with tadalafil once daily will allow men to return to normal erectile function in those who did not have normal erectile function following as-needed (PRN) Phosphodiesterase Type 5 (PDE5) Inhibitor treatment.

Timeline

Start
2010-08
Primary completion
2012-01
Completion
2012-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator Tadalafil Small molecule 5 mg Oral

Indications